Shares of Intra-Cellular Therapies ITCI fell 2% in pre-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share decreased 41.18% year over year to ($0.96), which missed the estimate of ($0.91).
Revenue of $1,907,000 higher by 0.00% from the same period last year, which missed the estimate of $3,030,000.
Guidance
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
Conference Call Details
Date: Aug 10, 2020
Time: 08:30 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/wen7vxux
Recent Stock Performance
52-week high: $43.56
52-week low: $6.75
Price action over last quarter: Up 7.13%
Company Overview
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
